Pegloticase is a recombinant uricase used for the treatment of chronic gout in adult patients refractory to conventional therapy. Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin.
- Mechanism
- Curator reviewed · 6 references
Gout is characterized by the presence of hyperuricemia, a biochemical abnormality where the concentration of serum urate is higher or equal to 6.8 mg/dl. Pegloticase is a PEGylated recombinant modified mammalian urate oxidase (uricase) that converts uric acid into allantoin, an inert and highly water-soluble metabolite, with hydrogen peroxide and carbon dioxide as by-products of this reaction. Allantoin is excreted by the kidneys, and this reduces the amount of uric acid in serum. The reduction in serum uric acid induces a concentration gradient that promotes the migration of urate from joints and tissues, making it readily available for allantoin conversion.
- Primary indication
- Pegloticase is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.Curator reviewed · 1 structured indication
- Formula / weight
- C1549H2430N408O448S8 · 34192.8533 Da
- First approval
- United States, 2010
- Also known as
- Puricase
- Brand names
Resolves to
What you can answer from here — as of February 17, 2024
Which other approved drugs treat the same conditions as Pegloticase, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account